Dr. Andrew Livingston shares an update on his osteosarcoma research, funded by MIB Agents: "CD73 The Next Immunotherapy Target for OS". After a presentation on this research, Dr. Livingston answers questions from attendees.
Guest Information: J. Andrew Livingston, MD
Assistant Professor, Department of Sarcoma Medical Oncology
Department of Pediatrics Co-leader for the MDACC Adolescent and Young Adult Program
University of Texas MD Anderson Cancer Center
OsteoBites Panelists are Amanda Braunfeld Levine of the closed FB group "Bone Cancer Support...for lives touched by Osteosarcoma & Ewing Sarcoma" and Florencia Pistritto of the Facebook Group "Osteosarcoma and Ewing's Sarcoma Support Group". Hosted by Ann Graham, President of MIB Agents.
MIB Agents is a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer. More information/Help us fund research at www.mibagents.org